

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 47/48		A1	(11) International Publication Number: WO 95/10304 (43) International Publication Date: 20 April 1995 (20.04.95)
<p>(21) International Application Number: PCT/EP94/03154</p> <p>(22) International Filing Date: 21 September 1994 (21.09.94)</p> <p>(30) Priority Data: 9320781.9 8 October 1993 (08.10.93) GB</p> <p>(71) Applicant (<i>for all designated States except US</i>): PHARMACIA S.P.A [IT/IT]; Via Robert Koch, 1.2, I-20152 Milan (IT).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): ANGELUCCI, Francesco [IT/IT]; Via G. Washington, 106, I-20146 Milan (IT). SUARATO, Antonino [IT/IT]; Via Degli Imbriani, 39, I-20158 Milan (IT).</p>		<p>(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: POLYMER-BOUND CAMPTOTHECIN DERIVATIVES</p> <p>(57) Abstract</p> <p>A polymeric conjugate consists essentially of: (i) from 60 to 99 mol % of N-(2-hydroxypropyl)methacryloylamide units represented by formula (1); (ii) from 1 to 40 mol % of 20-O-(N-methacryloylglycylaminoacyl)camptothecin units represented by formula (2) wherein [A] is a spacer group having respective terminal amino and carbonyl groups which are separated by at least three atoms and O-CPT represents a residue of a camptothecin, the C-20 hydroxy group of the camptothecin being linked to the terminal carbonyl group of the spacer group [A]; and (iii) from 0 to 10 mol % of N-methacryloylglycine or N-(2-hydroxypropyl)methacryloylglycinamide units represented by formula (3) wherein Z represents hydroxy or a residue of formula -NH-CH₂-CH(OH)-CH₃.</p>			
$\begin{array}{c} \\ \text{CH}_2 \\ \\ \text{CH}_3-\text{C}-\text{CO}-\text{NH}-\text{CH}_2-\text{CHOH}-\text{CH}_3 \end{array} \quad (1)$ $\begin{array}{c} \\ \text{CH}_2 \\ \\ \text{CH}_3-\text{C}-\text{CO}-\text{Gly}-[\text{A}]-\text{O}-\text{CPT} \\ \end{array} \quad (2)$ $\begin{array}{c} \\ \text{CH}_2 \\ \\ \text{CH}_3-\text{C}-\text{CO}-\text{Gly}-\text{Z} \\ \end{array} \quad (3)$			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

POLYMER-BOUND CAMPTOTHECIN DERIVATIVES

The present invention refers to water soluble polymer-bound camptothecin and polymer-bound camptothecin derivatives endowed with antitumour activity, to a process 5 for their preparation and to pharmaceutical compositions containing them.

Camptothecin is an alkaloid isolated from the leaves and bark of Camptotheca acuminata; other analogs of camptothecin are also known and were prepared by 10 semisynthesis from camptothecin or by total synthesis: see J.Amer.Chem.Soc. 94(10), 3631 (1972); J.Chem.Soc.D. (7), 404 (1970); US-A-4,981,969 (Jan.1, 1991); US-A-5,049,668 (Sep.17, 1991).

Camptothecin has a pentacyclic structure consisting 15 of a fused ring system forming a quinoline ring (rings A and B), a pyrrolidine ring (ring C), a pyridone ring (ring D) and an α -hydroxy- δ -lactone moiety (ring E). Camptothecin and several of its A ring-substituted derivatives exhibit 20 antitumour activity against a variety of solid tumour lines, including cell lines resistant to clinically available chemotherapeutic agents [see: J.Clin.Pharmacol. 30, 770 (1990); Cancer Chemother.Pharmacol. 28, 192 (1991)].


Camptothecin, as well as most of its derivatives, 25 is practically insoluble in vehicles suitable for parenteral administration due to weak basicity of the quinone nitrogen atom. In order to solubilize camptothecins, several water soluble prodrugs have been proposed such as 20-O-phosphate or 20-O-acylamino derivatives which can be protonated by mineral acids, thus allowing water solubility: 30 see US-A-4,943,579 (Jul. 24, 1990). Toxic side effects, including haematological and gastrointestinal ones, are associated with the administration of these drugs. Numerous attempts have been made to improve therapeutic index of

- 2 -


camptothecin by modifying its structure.

The present invention provides polymeric conjugates of camptothecins which are water soluble and possess antitumor activity in vivo and decreased toxicity. More particularly, the invention provides a polymeric conjugate which is denoted herein as A and which consists essentially of:


(i) from 60 to 99 mol % of N-(2-hydroxypropyl) methacryloylamide units represented by formula 1:



15 (ii) from 1 to 40 mol % of 20-O-(N-methacryloylglycyl-aminoacyl)camptothecin units represented by formula 2



wherein [A] is a spacer group having respective terminal amino and carbonyl groups which are separated by at least three atoms and O-CPT represents a residue of a camptothecin, 25 the C-20 group of the camptothecin being linked to the terminal carbonyl group of the spacer group [A]; and (iii) from 0 to 10 mol % of N-methacryloylglycine or N-(2-hydroxy-propyl)methacryloylglycinamide units represented by formula 3:



- 3 -


wherein Z represents hydroxy or a residue of formula -NH-CH₂-CH(OH)-CH₃.

The invention also provides a process for preparing a polymeric conjugate as defined above, which process 5 comprises reacting a 20-O-acylamino-camptothecin derivative of formula 7:




7

- 10 wherein [A] and O-CPT are as defined above, with a polymer consisting essentially of:
 (i) from 60 to 99 mol % of N-(2-hydroxypropyl)methacryloyl-amide units represented by formula 1:



1

- and
 20 (iv) from 40 to 1 mol % of N-methacryloylglycine units represented by formula 4:



4

- wherein R₂ is (a) the residue of an active ester or (b) hydroxy; and optionally displacing the remaining active ester groups with 1-amino-2-propanol.
- 30 The polymeric conjugate A contains the N-(2-hydroxypropyl)methacryloylamide units represented by the formula 1 in a proportion of 60 mol % or more, for example at least 80 mol % or at least 85 mol %. These units may be

- 4 -

present in an amount from 91 to 98 mol %. The conjugate may also contain from 1 to 40 mol % of the 20-O-(N-methacryloylglycyl-aminoacyl)camptothecin units represented by the formula 2, for example from 1 to 20 mol % of such 5 units. The conjugate may contain from 1 to 8 mol %, for example from 2 to 6 mol %, of these units.

The spacer group [A] may be from three to twelve, for example from six to nine, atoms long. Typically, the group is susceptible to intracellular hydrolysis. Preferably 10 it is resistant to extracellular hydrolysis. The spacer group may be a peptide spacer, for example from 1 to 4 or 2 to 4 amino acid residues long. The spacer may thus be a dipeptide, tripeptide or tetrapeptide.

Preferably the spacer group [A] is selected from 15 Ala-Gly, Phe-Gly, Phe-Phe, Leu-Gly, Val-Ala, Phe-Ala, Leu-Phe, Leu-Ala, Phe-Leu-Gly, Phe-Phe-Leu, Leu-Leu-Gly, Phe-Tyr-Ala, Phe-Gly-Phe, Phe-Phe-Gly and Phe-Leu-Gly-Phe. Alternatively the spacer group [A] is a group of formula - 20 HN-Y-CO- in which Y is C₃-C₆ linear or branched alkyl such as -(CH₂)_n wherein n is 3, 4, 5 or 6.

Alternatively, the spacer [A] is a group of formula Ala-Gly-NH-Y-CO-, Phe-Gly-NH-Y-CO-, Phe-Phe-NH-Y-CO-, Leu-Gly-NH-Y-CO-, Val-Ala-NH-Y-CO-, Phe-Ala-NH-Y-CO-, Leu-Phe-NH-Y-CO-, Leu-Ala-NH-Y-CO-, Phe-Leu-Gly-NH-Y-CO-, Phe-Phe-Leu-NH-Y-CO-, Leu-Leu-Gly-NH-Y-CO-, Phe-Tyr-Ala-NH-Y-CO, Phe-Gly-Phe-NH-Y-CO-, Phe-Phe-Gly-NH-Y-CO- or Phe-Leu-Gly-Phe-NH-Y-CO- wherein Y has the same meaning as above.


A residue of a camptothecin is denoted by O-CPT. The camptothecin may be camptothecin itself or an analogue 30 thereof such as an A-ring analogue. Such an A-ring analogue is thus camptothecin substituted on the A-ring. The camptothecin may be in the natural S form or in the R form or in a mixture of R and S forms (racemic mixture). Suitable

- 5 -

camptothecin residues O-CPT are denoted by the formula 5:

5


5



wherein R₁ represents, for example, hydrogen, hydroxy, nitro or amino or a methylenedioxy group bonded to two adjacent carbon atoms on the A-ring. Preferably R₁ represents hydrogen, 9-, 10-, 11- or 12-hydroxy, 9- or 10-nitro, 9- or 10-amino or 10,11-methylenedioxy. More preferred are camptothecin residues of formula 6:

15

6



20

wherein R₁ is as defined above.

Preferably, the units of formula 2 are present in an amount of from 1 to 10 mol % such as 0.5 to 5 mol %. Also preferably, the camptothecin content is from 1 to 10 % (w/w), more preferably from 4 to 8 % (w/w), based on the polymeric conjugate.

The invention also provides a 20-O-acylamino-camptothecin derivative of formula 7 as defined above. The present invention further provides a process for preparing a 20-O-acylamino-camptothecin derivative of formula 7, which process comprises condensing a camptothecin with a N-


- 6 -

protected aminoacyl derivative of formula 8:



8

wherein [A] is as defined above and R_3 represents an amino-protecting group, such as t-boc, CBZ, Fmoc, triphenylsilyl, 5 diphenylmethylene or triphenylmethyl, and P is a residue of an activated ester, such as p-nitrophenoxy, pentafluorophenoxy or N-hydroxysuccinimido, in the presence of an activating agent such as 4-dimethylaminopyridine, to give a N-protected-20-O(acylamino) compound represented by 10 formula 9:



wherein R_3 , [A] and [O-CPT] are as defined above; and 15 removing the N-protecting group from the resulting compound.

Preparation of compounds of formula 8 follows standard synthetic procedures that are known from the literature. Suitable N-protected-aminoacyl derivatives of formula 8 include N-trityl-L-phenylalanyl-L-leucyl-glycyl p-nitrophenyl ester (8a) or N-trityl-glycyl-L-leucyl-glycyl p-nitrophenylester (8b), or 6-N-trityl-hexa-noyl p-nitrophenyl ester (8c). Some derivatives of formula 8 and their preparation are described also in our copending International Patent Application No. PCT/EP94/01100.

25 Thus, for example, a camptothecin may be allowed to react with a molar excess, for example up to a five-fold molar excess or more, especially 2 mol. equivalent, of a N-protected-aminoacyl derivative of formula 5 in anhydrous solvent such as anhydrous dimethylformamide or 30 dimethylsulfoxide in the presence of activating agent such as 4-dimethylaminopyridine. In this manner, the protected amino acid is introduced at position C-20 on the camptothecin molecule. The reaction can typically be effected for from 8


- 7 -

to 24 hours. The reaction is typically carried out at a temperature from 15 to 40°C. It should be noted that, following such reaction conditions, 9-aminocamptothecin regiospecifically reacts at the C-20-hydroxy position due the 5 weak basicity of the 9-amino group.

The amino-protecting group R₃ is removed by an appropriate deprotecting agent to give the 20-O-acylamino-camptothecin derivative of formula 7. Deprotection may therefore be achieved by mild acid treatment, such as 10 treatment with acetic acid, or by reduction. Hydrogenolysis may therefore be employed.

The condensation of the 20-O-acylamino-camptothecin derivative of formula 7 with the polymer consisting essentially of from 60 to 99 mol % of the N-(2-hydroxypropyl)-methacryloylamide units of formula 1 and from 15 40 to 1 mol % of N-methacryloylamide units of formula 4, and the optional subsequent displacement of the remaining active ester groups, are carried out in conditions capable of preserving the nature of linkage between camptothecins and 20 spacers [A] as well as that of the conjugate.

Polymers consisting essentially of from 60 to 99 mol % of the N-(2-hydroxypropyl)-methacryloylamide units of formula 1 and from 40 to 1 mol % of N-methacryloylglycine units of formula 4, are prepared by copolymerization of N-(2-hydroxypropyl)methacrylamide with N-methacryloyl-glycine or N-methacryloylglycine active-ester derivatives, as 25 described in Makromol.Chem. 178, 2159 (1977). R₂ may represent a phenoxy group which is substituted on the phenyl ring by one or more electron-withdrawing groups. 30 Examples of suitable electron-withdrawing groups include nitro (-NO₂) and halogen. R₂ is preferably the leaving group:



- 8 -

wherein L is an electron withdrawing group, for example -NO₂, or a halogen such as fluorine or chlorine, and m is an integer of 1 to 5, typically 1 to 3, preferably 1 or 2.

- 5 Preferably R₂ is a p-nitrophenoxy group or a 2,4-dichlorophenoxy group.

Preferably, the reaction between a polymer in which R₂ represents (a) the residue of active ester and a compound of formula 7 to prepare the polymer conjugate of the invention is carried out in an anhydrous polar organic solvent such as dimethyl-formamide or dimethylsulfoxide. The reaction can typically be effected for from 8 to 24 hours. The reaction is typically carried out at temperature from 15 to 30°C, preferably at room temperature for 15 hours; then the aminolysis of the remaining active ester can be performed in the presence of 1-amino-2-propanol at room temperature, for from 0.5 to 1 hour. The conjugate suitably is precipitated with acetone, dissolved in ethanol and reprecipitated with acetone.

20 In another method, in order to prepare a polymer conjugate of the invention, the reaction between a polymer in which R₂ represents hydroxy group (b) and a compound of formula 7 is carried out in an anhydrous polar solvent such as dimethylformamide or dimethylsulfoxide in the presence of 25 a condensing agent such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline. The reaction can typically be effected for from 8 to 24 hours. The reaction is typically carried out at a temperature from 15 to 30°C, preferably at room temperature for 15 hours; then the conjugate can be precipitated with 30 acetone, dissolved in ethanol and reprecipitated with acetone.

For example, the polymer in which R₂ represents (a) the residue of an active ester, provided at a concentration

- 9 -

of 15% (weight/volume) in anhydrous dimethylsulfoxide, is treated with a 20-O-aminoacyl camptothecin derivative of formula 7, 3% (w/v), at room temperature for 15 hours. Then 1-amino-2-propanol, 0.1% (w/v) is added and the reaction 5 mixture is kept at room temperature for 1 hour. The conjugate can be precipitated with acetone, then dissolved with absolute ethanol at a concentration of 10% (w/v) and precipitated again with acetone to give neutral camptothecin conjugate according to the invention.

10 In another example, the polymer in which R₂ represents (b) hydroxy, provided at a concentration of 15% (weight/volume) in anhydrous dimethylsulfoxide, is treated with a 20-O-aminoacyl camptothecin derivative of formula 7, 3% (w/v), in the presence of 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, 1.3% (w/v), at room temperature for 15 hours. Acetone then is added to cause precipitation, the precipitate is dissolved with absolute ethanol at a concentration of 10% (w/v) and precipitation is again caused by acetone addition to give a polymeric conjugate according 15 to the invention.

The content of active drug, such as camptothecin or its A-ring analogues, in polymeric conjugates of the invention is determined by HPLC or absorbance spectroscopy analysis.

25 Polymer conjugates of camptothecin and its A-ring analogues described in the present invention are endowed with improved water solubility and decreased toxicity. The conjugates exhibit good water solubility, biocompatibility and release camptothecins in the plasma or after 30 internalization into cells by enzymatic cleavage.

10

Biological Activity

Copolymer of N-(2-hydroxypropyl)methacrylamide, 20-O-[N-methacryloylglycyl-L-phenylalanyl-L-leucylglycyl] camptothecin and N-(2-hydroxypropyl) methacryloylglycinamide (A2) was tested in nude mice transplanted with HT29/Colon Carcinoma (Table 1) and in mice bearing early and advanced M5076 murine reticulosarcoma (Table 2 and 3) in comparison with free camptothecin (CPT).

When compared with camptothecin, a striking higher activity in all experiments was observed for the polymer bound camptothecin derivative A2. It is noteworthy that cured mice were found in the experiment on HT29/Colon Carcinoma.

The antitumor activity was tested with the same treatment schedule for A2 and CPT. It should be noted that polymer-bound camptothecin A2 and was found highly water soluble and was dissolved in saline and was administered i.v., whereas CPT was dissolved in a mixture of water and Tween 80.

Drug preparation and administration.

Compound A2 was dissolved in distilled water immediately prior to use and the concentration was checked spectrophotometrically at 370 nm ($E_{1\%} 57.18$). Camptothecin (CPT) was dissolved in sterile water with 10% tween. Treatment was administered i.v. in a volume of 10 ml/kg of body weight and control mice were treated with sterile water.

Tumors.

HT29 Colon Carcinoma was transplanted s.c. in athymic Swiss/nu/ mice using 15-20 mg of tumor brei.

11

M5076 muine reticulosarcoma was maintained by serial i.m. passages and transplanted s.c. (5×10^5 cells/mouse) in compatible C57B1/6 mice.

- All animals were from Charles River Calco, Como, Italy.
5 Ten mice/group for conventional and eight for athymic mice were used.
The conventional mice weighed 20 to 22 g and were kept under standard laboratory conditions.
The mouse colony was routinely tested for the absence of
10 antibodies to a panel of pathogens including Mouse Hepatitis, Sendai Virus and *Mycoplasma Pulmonis*.

Evaluation of antitumor activity and toxicity.

- 15 Tumor growth was assesed by caliper measurement and the tumor weight estimated according to Geran et al. (see: Cancer Chem. Rep., Part 3, 3 (2) ed. 3, pp 1-103, 1972). The antitumor activity is expressed as percentage of inhibition of tumor growth (%T/I) using the following
20 formula:

$$100 - \frac{(\text{median tumor weight of treated mice})}{(\text{median tumor weight of control mice})} \times 100$$

- 25 The median increase in survival time (T/C%) was calculated using the following formula:

$$\frac{(\text{median survival time treated mice})}{(\text{median survival time control mice})} \times 100$$

Cured mice are mice without tumor at the end of the experiment.

12

Toxicity was evaluated on the basis of the body weight reduction and gross autopsy findings, mainly in terms of reduction of spleen and liver size.

5 Table 1. Antitumor Activity of Compound A2 in comparison with Camptothecin (CPT) against HT29/Colon Carcinoma.

Compound	dose ⁽¹⁾ mg/kg	treatment schedule	% tumor inhib.	TOX ⁽²⁾ 0/18	cured ⁽³⁾ mice
A2	7.5	iv q4dx6	96	0/18	3/18
CPT	7.5	iv q4dx6	83	0/10	0/10

(1) expressed as CPT equivalent.

10 (2) number of toxic deaths/total number of mice

(3) tumor free mice 90 days after tumor implant

15 Table 2. Antitumor Activity of Compound A2 in comparison with Camptothecin (CPT) against early M5076 murine reticulosarcoma.

Compound	dose ⁽¹⁾ mg/kg	treatment schedule	% tumor ⁽³⁾ inhib.	T/C	TOX ⁽²⁾ %
A2	7.5	iv 1,6,9	100	171	0/10
CPT	7.5	ip 1,6,9	100	165	0/10

20

(1) expressed as CPT equivalent.

(2) number of toxic deaths/total number of mice

(3) % tumor inhibition was estimated one week after the last treatment.

25

13

Table 3. Antitumor Activity of Compound A2 in comparison with Camptothecin (CPT) against advanced M5076 murine reticulosarcoma. Treatment schedule iv on day 16, 20, 24 28, 31, 35.

5

Compound	Dose ⁽¹⁾ mg/kg	%tumor ⁽³⁾ inhibition	T/C	TOX ⁽²⁾
A2	10.0	80	174	0/10
	15.0	95	183	0/10
CPT	7.5	72	173	0/10

(1) expressed as CPT equivalent.

(2) number of toxic deaths/total number of mice

10 (3) % tumor inhibition was estimated at day 34.

Toxicity.

- 5 Toxicity of copolymer of N-(2-hydroxypropyl)methacryl-
 amide, 20-O-[N-methacryloylglycyl-L-phenylalanyl-L-
 leucylglycyl] camptothecin and N-(2-hydroxypropyl)
 methacryloylglycinamide (A2) was evaluated in healthy
 C57Bl/F mice, treatment i.v. in comparison with
 10 camptothecin (CPT).

The LD₁₀⁽¹⁾ and LD₅₀⁽²⁾ values in C57Bl/F mice are as follows:

15	Compound	LD ₁₀ mg/kg	LD ₅₀ mg/kg
	A2	129	151
20	CPT	16.9	43.4

(1) LD₁₀ : dose inducing 10% of death mice.

(2) LD₅₀ : dose inducing 50% of death mice.

- 25 The low toxicity of polymer-bound camptothecin derivative A2 allows to administer higher doses of product and to reach equivalent or better results than that with camptothecin.
- 30 The polymer-bound camptothecins have anti-tumor activity. They inhibit topoisomerase I. They are useful in the treatment of leukaemia and colon and rectal tumors in particular.

- 15 -

A human or animal can therefore be treated by a method comprising administering thereto a therapeutically effective amount of a polymeric conjugate of the invention. The condition of the human or animal patient can thus be
5 improved.

The dosage range adopted will depend on the route of administration and on the age, weight and condition of the patient being treated. The polymeric conjugates are typically administered by the parenteral route, for example
10 intramuscularly, intravenously or by bolus infusion. A suitable dose range is from 1 to 1000 mg of camptothecin equivalent per m² body surface area, for instance from 10 to 50 mg/m².

The polymeric conjugates may be formulated into a
15 pharmaceutical composition together with a pharmaceutically acceptable carrier or diluent. Typically the polymeric conjugates are formulated for parenteral administration, for example by dissolution in water for injection or physiological saline.

20 The following Examples illustrate the invention without limiting it. Throughout the specification, amino acid residues are shown in the three-letter code according to Eur.J.Biochem. 138, 9-37, 1984.

25 Stability of polymeric conjugates in murine or human plasma was assessed in the following manner: to 1 ml of murine or human plasmas, various concentrations of a polymeric conjugate of the invention A were added and at appropriate time (24, 48, 72, 96 hours) 100 µl samples were collected and stored at -70°C until further processing.

30 Each sample was extracted by adding 100 µl of 0.25M phosphoric acid, 500 µl CH₃CN and 700 µl ethyl acetate and vigorously shaking for 20 minutes at 4°C. After that time, the sample was spun at 15000 x g for 10 minutes and the

- 16 -


supernatant was separated. To the residue was added 300 μ l of CH₃CN and 500 μ l was spun at 15000 x g for 10 minutes. The supernatant was separated. The organic phases were pooled and evaporated using a high vacuum centrifuge. The 5 sample was recovered by adding 500 μ l of MeOH/water pH2 (70/30 by volume) and injected into HPLC apparatus for determining the total drug percentage content.

HPLC system

10 Column : μ Bondapak C10 (Waters) 3.9 x 300 mm
Flow rate : 1.5 ml/min
Detector : Spectrophotometer Fluorescence 650-40
(Perkin Elmer); emission 434 nm (slit 5);
excitation 370 nm (slit 5)
15 Injection : 10 μ l
Mobile Phase : 51.5 % MeOH, 47.5 % water, 1 % phosphoric acid

Example 1

20 6-N-trityl-hexanoyl p-nitrophenyl ester (8c)



8c

6-Aminocaproic acid (6.5 g, 50 mmol) suspended in a mixture 25 of dry chloroform (75 ml) and dry acetonitrile (15 ml) was added with trimethylsilyl chloride (6.3 ml, 50 mmol) and kept under reflux for two hours under vigorous stirring. After that, the mixture was cooled and added in sequence were triethylamine (13.7 ml, 100 mmol) and trityl chloride (14 g, 30 50 mmol) dissolved in dry chloroform (100 ml). The mixture was let to stand overnight at room temperature, then methanol (10 ml) was added and the reaction mixture was concentrated under reduced pressure. The residue was picked up with cold


- 17 -

aqueous 5% citric acid (200 ml) and extracted with ethyl acetate (200 ml). The organic phase was separated and extracted with cold aqueous 1N sodium hydroxide (200ml). The aqueous phase was separated, cooled with ice, brought to pH 5 with acetic acid and extracted with ethyl acetate (2x100 ml). The organic solvent was removed under reduced pressure to afford, after crystallization from ethyl acetate, 6-N-trityl-hexanoic acid (16 g). This material was dissolved in anhydrous tetrahydrofuran (150 ml) and treated with p-nitrophenol (5.6 g, 400 mmol) and dicyclohexylcarbodiimide (8.4 g, 40 mmol) at 0°C for one hour under stirring, then overnight at 8°C. After that, the reaction mixture was filtered, cooled at 0°C for two hours and filtered again. Finally, the organic solvent was removed under reduced pressure and the residue was crystallized with ethyl ether to afford the title compound 8c (16.4 g). TLC on Kieselgel plates F₂₄₅ (Merck), eluting system ethyl ether/n-hexane (1:1 by volume) R_f=0.6; FD-MS: m/z [M+H]⁺ 495 H¹NMR (90 MHz, CDCl₃) δ:

1.1-1.9 (m, 6H); 2-2.5 (m, 4H); 5.7-5.9 (m, 2H, NH, -COOH); 7.2-7.7 (m, 15 H).

Example 2

25 20-O-(6-aminohexanoyl)camptothecin (7c)



Camptothecin (6a, R₁=H, 0.7 g, 2 mmol) was dissolved in dry

- 18 -

dimethylsulfoxide (100 ml) and added with 6-N-trityl-hexanoyl p-nitrophenyl ester (8c, 2 g, 4 mmol), prepared as described in Example 1, and 4-dimethylaminopyridine (0.24 g, 2 mmol). The reaction mixture was kept at room temperature
 5 for 48 hours, then diluted with chloroform (400 ml) and washed with water (3x100 ml). The organic phase was separated, dried over anhydrous sodium sulphate and concentrated to small volume under reduced pressure. The crude material was flash chromatographed on silicic acid
 10 column eluting with chloroform to afford 20-O-(6-N-trityl-hexanoyl)camptothecin (0.6 g). TLC on Kieselgel plates F₂₄₅ (Merck), eluting system chloroform/methanol (95:5 by volume) R_f=0.4. The N-protected derivative was treated with 95% trifluoroacetic acid (10 ml) at room temperature for 50 minutes. After removal of the acid under reduced pressure,
 15 the title compound 7c was collected with ethyl ether. Yield 0.4 g. TLC on Kieselgel plates F₂₄₅ (Merck), eluting system methylene chloride/methanol/acetic acid/water (80:20:7:3) R_f=0.6. FD-MS: m/z [M+H]⁺ 462

20


Example 3

20-O-(L-Phenylalanyl-L-Leucyl-Glycyl)camptothecin (7b)

25

Phe-Leu-Gly

7b



30

N-trityl-L-phenylalanyl-L-leucylglycine p-nitrophenyl ester (8a, 1.4 g, 2 mmol) prepared as previously described in UK Application No. 9309663.4, camptothecin (6a, R₁=H, 0.35g,

- 19 -

1 mmol) and 4-dimethylaminopyridine (0.12 g, 1 mmol) were dissolved with dry dimethylsulfoxide (50 ml) and stirred at room temperature for 20 hours. After that, the reaction mixture was diluted with chloroform (400 ml) and washed with water (3x100 ml). The organic phase was separated, dried over anhydrous sodium sulphate and concentrated to small volume under reduced pressure. The crude material was flash chromatographed on silicic acid column eluting with a mixture of chloroform/methanol (99.5/0.5 by volume). The fractions containing the N-protected derivative of the title compound were pooled, concentrated to dryness, dissolved with aqueous 75% acetic acid (30 ml) and kept at room temperature for one hour. The reaction mixture was treated with solid sodium hydrogen carbonate to pH 7 and extracted with chloroform (400 ml). After removal of the organic solvent, the title compound 7b was crystallized from ethyl ether. Yield 0.16 g. TLC on Kieselgel plates F₂₄₅ (Merck), eluting system chloroform/methanol (9:1 by volume) R_f=0.35
FD-MS:m/z [M+H]⁺ 667
1H-NMR (400MHz, CDCl₃) δ:
0.81 (d, J=6.5Hz, 3H, δ-Leu); 0.82 (d, J=6.6Hz, 3H, δ'-Leu);
0.98 (t, J=7.6Hz, 3H, CH₃-CH₂); 1.25 (m, 1H, β-Leu); 1.39 (m,
1H, -Leu); 1.56 (m, 1H, β'-Leu); 1.98 (dd, J=6.4Hz,
J=13.5Hz, 1H, β-Phe); 2.1-2.4 (m, 2H, CH₂CH₃); 2.48 (d,
J=7.0Hz, 1H, NH-Phe); 2.77 (dd, J=4.7Hz, J=13.5Hz, 1H, β'-
Phe); 3.41 (m, 1H, α-Phe); 4.0-4.3 (m, 3H, α-Gly + α'-Gly +
α-Leu); 5.20-5.27 (two-d, J=19.9Hz, 2H, 5-CH₂); 5.41-5.68
(two-d, J=17.3Hz, 2H, 17-CH₂); 6.35 (t, J=5.3Hz, 1H, NH-Gly);
6.76 (d, J=7.6Hz, 1H, NH-Leu); 6.8-7.3 (m, 21H,
30 4x(C₆H₅) + 14-H).


- 20 -

Example 49-amino-20-O-(L-Phenylalanyl-L-Leucyl-Glycyl)camptothecin

(7c)

5

10



7c


N-trity-L-phenylalanyl-L-leucylglycine p-nitrophenyl ester (8a, 1.14 g, 2 mmol), 9-amino-camptothecin (6b, $R_1=NH_2$, 0.363 g, 1 mmol), 4-dimethylaminopyridine (0.12 g, 1 mmol) were reacted in dry dimethylsulfoxide (20 ml) at room temperature as described in Example 3 to give the title compound 7c (0.31 g). TLC on Kieselgel plates F_{245} (Merck), eluting system chloroform/methanol (9:1 by volume) $R_f = 0.2$. FD-MS: $m/z [M+H]^+$ 682; 1H -NMR (400MHz, $CDCl_3$) δ :

20 0.82 (d, $J=6.5Hz$, 6H, δ -Leu + δ' -Leu); 1.00 (t, $J=7.6Hz$, 3H, CH_2CH_3); 1.25 (m, 1H, β -Leu); 1.41 (m, 1H, α -Leu); 1.59 (m, 1H, β' -Leu); 1.99 (dd, $J=6.2Hz$, $J=13.5Hz$, 1H, β -Phe); 2.1-2.4 (m, 2H, CH_2CH_3); 2.47 (d, $J=6.5Hz$, 1H, NH-Phe); 2.79 (dd, $J=4.7Hz$, $J=13.5Hz$, 1H, β' -Phe); 3.43 (m, 1H, α -Phe); 4.0-4.3 (m, 5H, 9-NH₂ + α -Leu + α -Gly + α' -Gly); 5.04-5.15 (two-d, $J=19.9Hz$, 2H, CH_2); 5.39-5.66 (two-d, $J=17.0Hz$, 2H, 17-CH₂); 6.44 (t, $J=5.3Hz$, 1H, NH-Gly); 6.81 (d, $J=7.6Hz$, 1H, NH-Leu); 6.85 (m, 3H, 10-H +); 7.0-7.4 (m, 19H, 30 3x(C_6H_5) + - + 14-H); 7.51 (m, 1H, 11-H).

- 21 -

Example 5

Copolymer of N-(2-hydroxypropyl)methacrylamide, 20-O-[N-methacryloylglycyl-(6-aminohexanoyl)]camptothecin and N-(2-hydroxy-propyl)methacryloylglycinamide (A1:x=96 %, z=1)




Copolymer of N-(2-hydroxypropyl)methacrylamide and N-methacryloylglycine p-nitrophenylester (0.15 g), prepared as described in Makromol.Chem., 178, 2159 (1977), containing 2.7×10^3 equivalents of p-nitrophenylester, was reacted with 20-O-(6-aminohexanoyl)camptothecin (7c, 18 mg), prepared as described in Example 2, in dry dimethylsulfoxide (1 ml) at room temperature for 18 hours, then with 1-amino-2-propanol (2 μ l) for one hour at room temperature. After that, the reaction mixture was treated with acetone (70 ml). The precipitate was collected, redissolved with anhydrous ethanol (5 ml) and reprecipitated with acetone (50 ml) to give the title conjugate A1 (0.14 g) containing 5 % (w/w) of

- 22 -

camptothecin. After plasma incubation, conjugate A1 releases 10% of camptothecin after 120 hours.

Example 4

- 5 Copolymer of N-(2-hydroxypropyl)methacrylamide, 20-O-[N-methacryloylglycyl-L-phenylalanyl-L-leucylglycyl] camptothecin and N-(2-hydroxypropyl)methacryloylglycinamide (A2:x=96, y=2.2, z=1.8)




- 30 Copolymer of N-(2-hydroxypropyl)methylacrylamide and N-methacryloylglycine p-nitrophenylester (0.15 g, containing 2.7×10^3 equivalents of p-nitrophenylester) and 20-O-(Glycyl-L-leucyl-L-phenylalanyl)camptothecin (7b, 20 mg), prepared as described in Example 3 were reacted in dry dimethylsulfoxide (1 ml), then with 1-amino-2-propanol as described in Example 6 to give the title conjugate A2 (0.14 g), containing 4.8 % w/w of camptothecin. After plasma incubation, conjugate A2 released 100% of camptothecin after 60 hours.

- 23 -

Example 7

Copolymer of N-(2-hydroxypropyl)methacrylamide, 9-amino-20-O-[N-methacryloylglycyl-L-phenylalanyl-L-leucylglycyl] camptothecin and N-(2-hydroxypropyl)methacryloylglycinamide
 5 (A3:x=96, y=3, z=1)




The title conjugate was prepared by reacting copolymer of N-(2-hydroxypropyl)methacrylamide and N-methacryloylglycine p-nitrophenylester (0.15 g, containing 2.7×10^{-3} equivalents of p-nitrophenylester) and 9-amino-20-O-(Glycyl-L-leucyl-L-phenylalanyl)camptothecin (7c, 20 mg), prepared as described in Example 4 in dry dimethylsulfoxide (1 ml), then with 1-amino-2-propanol as described in Example 5. Yield 0.14 g, containing 6.3 % w/w of 9-amino-camptothecin. After plasma incubation, conjugate A3 releases 100% of camptothecin after 50 hours.


- 24 -

CLAIMS


1. A polymeric conjugate which consists
essentially of:
 (i) from 60 to 99 mol % of N-(2-hydroxypropyl)
 5 methacryloylamide units represented by formula 1:



- (ii) from 1 to 40 mol % of 20-O-(N-methacryloylglycyl-
aminoacyl)camptothecin units represented by formula 2



wherein [A] is a spacer group having respective terminal
amino and carbonyl groups which are separated by at least
 20 three atoms and O-CPT represents a residue of a camptothecin,
the C-20 hydroxy group of the camptothecin being linked to
the terminal carbonyl group of the spacer group [A]; and
 (iii) from 0 to 10 mol % of N-methacryloylglycine or N-(2-
hydroxy-propyl)methacryloylglycinamide units represented by
 25 formula 3:




wherein Z represents hydroxy or a residue of formula $-\text{NH}-\text{CH}_2-\text{CH}(\text{OH})-\text{CH}_3$.

- 25 -

2. A conjugate according to claim 1, wherein the spacer group [A] is selected from Ala-Gly, Phe-Gly, Phe-Phe, Leu-Gly, Val-Ala, Phe-Ala, Leu-Phe, Leu-Ala, Phe-Leu-Gly, Phe-Phe-Leu, Leu-Leu-Gly, Phe-Tyr-Ala, Phe-Gly-Phe, 5 Phe-Phe-Gly and Phe-Leu-Gly-Phe.
3. A conjugate according to claim 1, wherein the spacer group [A] is a group of formula -HN-Y-CO- in which Y is a C₃-C₆ linear or branched alkyl group or Ala-Gly-NH-Y-CO-, Phe-Gly-NH-Y-CO-, Phe-Phe-NH-Y-CO-, Leu-Gly-NH-Y-CO-, Val-10 Ala-NH-Y-CO-, Phe-Ala-NH-Y-CO-, Leu-Phe-NH-Y-CO-, Leu-Ala-NH-Y-CO-, Phe-Leu-Gly-NH-Y-CO-, Phe-Phe-Leu-NH-Y-CO-, Leu-Leu-Gly-NH-Y-CO-, Phe-Tyr-Ala-NH-Y-CO, Phe-Gly-Phe-NH-Y-CO-, Phe-Phe-Gly-NH-Y-CO-, or Phe-Leu-Gly-Phe-NH-Y-CO- wherein Y has the same meaning as above.
- 15 4. A conjugate according to any one of the preceding claims wherein O-CPT denotes a camptothecin residue of formula 6:

20



6

- 25 wherein R₁ represents hydrogen, hydroxy, nitro or amino or a methylenedioxy group bonded to two adjacent carbon atoms on the A-ring.

- 30 5. A conjugate according to any one of the preceding claims in which from 1 to 10 mol % of the said units of formula 2 are present.

6. A conjugate according to any one of the preceding claims in which the camptothecin content is from 1 to 10 % (w/w).

- 26 -

7. A process for preparing a polymeric conjugate as defined in claim 1, which process comprises reacting a 20-O-acylamino-camptothecin derivative of formula 7:

5


H[A]-O-CPT

7

wherein [A] and O-CPT are as defined in claim 1, with a polymer consisting essentially of:

(i) from 60 to 99 mol % of N-(2-hydroxypropyl)methacryloyl-
10 amide units represented by formula 1:

15




1

and

(iv) from 40 to 1 mol % of N-methacryloylglycine units represented by formula 4:

20



4

wherein R₂ is (a) the residue of an active ester or (b)
25 hydroxy; and
optionally displacing the remaining active ester groups with
1-amino-2-propanol.

8. A 20-O-acylamino-camptothecin derivative of formula 7 as defined in claim 7.

30 9. A process for preparing a 20-O-acylamino-camptothecin derivative of formula 7 as defined in claim 7, which process comprises condensing a camptothecin with a N-protected-aminoacyl derivative of formula 8:

- 27 -

R₃-[A]-P

8

wherein [A] is as defined in claim 1, R₃ represents an amino-protecting group and P is a residue of an activated ester, in
5 the presence of an activating agent to give a N-protected-20-O-(acylamino) compound represented by formula 9:

R₃-[A]-[O-CPT]

9

10 wherein R₃ and [A] are as defined above and O-CPT is as defined in claim 1; and removing the N-protecting group from the resulting compound.

10. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and, as active ingredient, a polymeric conjugate as claimed in any one of claims 1 to 6.

INTERNATIONAL SEARCH REPORT

Inte xnal Application No
PCT/EP 94/03154

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO,A,94 00156 (FARMITALIA CARLO ERBA) 6 January 1994 see claims ---	1-10
A	WO,A,93 14142 (UNIVERSITY OF UTAH) 22 July 1993 see page 19 - page 24 ---	1-10 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

'&' document member of the same patent family

Date of the actual completion of the international search

18 January 1995

Date of mailing of the international search report

31.05.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentstaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 94/03154

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF CONTROLLED RELEASE, vol.18, 1992, AMSTERDAM NL pages 123 - 132 V. SUBR ET AL. 'POLYMERS CONTAINING ENZYMATICALLY DEGRADABLE BONDS, XII. EFFECT OF SPACER STRUCTURE ON THE RATE OF RELEASE OF DAUNOMYCIN AND ADRIAMYCIN FROM POLY [N-(2-HYDROXYPROPYL)-METHACRYLAMIDE] COPOLYMER DRUG CARRIERS IN VITRO AND ANTITUMOUR ACTIVITY MEASURED IN VIVO.' see figure 1; table 2 ---	1-10
A	WO,A,93 13804 (FARMITALIA CARLO ERBA) 22 July 1993 see page 6 - page 7 ---	1-10
X	US,A,4 943 579 (B. RAO VISHNUVAJJALA) 24 July 1990 see claims ---	8,9
X	JOURNAL OF MEDICINAL CHEMISTRY, vol.36, 17 September 1993, WASHINGTON US pages 2689 - 2700 MONROE E. WALL ET AL. 'PLANT TUMOR AGENTS. 30. 1A,B SYNTHESIS AND STRUCTURE ACTIVITY OF NOVEL CAMPTOTHECIN ANALOGS' see page 2690; figure I ---	8,9
X	CANCER RESEARCH, vol.49, no.6, 1989 pages 1465 - 1469 JAXEL C. ET AL. 'STRUCTURE ACTIVITY STUDY OF THE ACTIONS OF CAMPTOTHECIN DERIVATIVES ON MAMMALIAN TOPOISOMERASE I : EVIDENCE FOR A SPECIFIC RECEPTOR SITE AND A RELATION TO ANTITUMOR ACTIVITY.' see the whole document -----	8,9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No	
PCT/EP 94/03154	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9400156	06-01-94	AU-B-	4323393	24-01-94
		CA-A-	2112482	06-01-94
		CN-A-	1079971	29-12-93
		CZ-A-	9400620	13-07-94
		EP-A-	0600062	08-06-94
		FI-A-	940733	16-02-94
		JP-T-	6509822	02-11-94
		NO-A-	940567	18-02-94
		PL-A-	302437	25-07-94
		US-A-	5362831	08-11-94
-----	-----	-----	-----	-----
WO-A-9314142	22-07-93	US-A-	5258453	02-11-93
		AU-B-	3593093	03-08-93
		CA-A-	2128330	22-07-93
		EP-A-	0621880	02-11-94
		FI-A-	943430	20-09-94
-----	-----	-----	-----	-----
WO-A-9313804	22-07-93	AU-B-	3346893	03-08-93
		EP-A-	0574571	22-12-93
		JP-T-	6505755	30-06-94
-----	-----	-----	-----	-----
US-A-4943579	24-07-90	NONE		
-----	-----	-----	-----	-----